T-CURX leverages Pantherna’s deep expertise and proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier T-CURX’ proprietary and clinically validated transposon-based non-viral CAR-T technology is potentiated and de-risked by Pantherna’s proprietary PTXmRNA® and PTXΔLNP® platforms, enabling the expansion of in vivo CAR-T therapies beyond cancer indications T-CURX’ acquisition of Pantherna builds